首页> 外文期刊>The Prostate >Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis
【24h】

Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis

机译:塔达拉夫尔对实验性自身免疫前列腺炎大鼠慢性盆腔疼痛和前列腺炎症的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background Experimental autoimmune prostatitis (EAP) shares important clinical features with clinical chronic prostatitis/chronic pelvic pain. We investigated the effect of tadalafil on pelvic pain and prostatic inflammation in a rat EAP model. Methods EAP was induced in rats by intradermal injection of rat prostate antigen and complete Freund's adjuvant on days 0 and 28. Rats were treated with tadalafil (2?mg/kg, p.o.; EAP‐tadalafil) or vehicle (EAP‐vehicle) once daily from day 0, while sham‐operated animals were treated with vehicle only (Sham). Tactile allodynia was measured on days 28, 35, and 42 by applying von Frey filaments to the lower abdomen as an index of pelvic pain. On day 42, the plasma immunoglobulin G (IgG) concentration and the testosterone/estradiol ratio were measured and histopathological analysis of the prostate was performed. Results Tactile allodynia in the pelvic region was observed on days 28, 35, and 42 after EAP induction. The tactile allodynia observed on day 42 was significantly reduced by repeated treatment with tadalafil. Plasma IgG concentrations increased after EAP induction but the increase was not changed by tadalafil treatment. Prostate tissues were characterized by epithelial necrosis, infiltration of neutrophils and/or lymphocytes to acini and stroma, and fibrosis, in addition to a high stroma‐to‐epithelium ratio. Tadalafil treatment significantly suppressed the severity of the lesions. Conclusions EAP rats developed pelvic pain, prostatic inflammation and increased plasma IgG concentrations. Tadalafil inhibited the chronic pelvic pain and prostatic inflammation, suggesting that its anti‐inflammatory action may contribute to its blocking of pain development in the EAP model.
机译:背景技术实验性自身免疫前列腺炎(EAP)与临床慢性前列腺炎/慢性骨盆疼痛分享重要的临床特征。我们调查了塔达拉夫尔对大鼠EAP模型中盆腔疼痛和前列腺炎症的影响。方法通过皮内注射大鼠前列腺抗原和完整的弗氏佐剂在第0天和28天的大鼠中诱发了EAP。每天用Tadalafil(2?Mg / kg,PO; EAP-TADALAFIL)或载体(EAP-XPRAB)治疗大鼠从第0天开始,虽然仅使用车辆(假)处理假手术动物。通过将von frey长丝施加到下腹部作为骨盆疼痛指数,在第28,35和42天测量触觉异常。在第42天,测量血浆免疫球蛋白G(IgG)浓度和睾酮/雌二醇比,并进行前列腺的组织病理学分析。结果在EAP诱导后的第28,35天和42天观察到骨盆区域中的触觉异常疼痛。通过用达拉非重复治疗,在第42天观察到的触觉异常。血浆IgG浓度在EAP诱导后增加,但达拉非治疗没有改变。除了高基质 - 上皮比例之外,前肢坏死,中性粒细胞和/或淋巴细胞浸润和纤维化,还表征了前列腺组织的特征。塔达拉非治疗显着抑制了病变的严重程度。结论EAP大鼠发育盆腔疼痛,前列腺炎症和增加的血浆IgG浓度。塔达拉非毒药抑制慢性盆腔疼痛和前列腺炎症,这表明其抗炎作用可能导致EAP模型中的疼痛发育造成促使。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号